Latest News and Press Releases

-- Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015 – -- Initiation of Later-Stage Bavituximab Trials to Expand Commercial Potential in NSCLC and...

TUSTIN, Calif., July 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing novel investigational products...

-Bavituximab Patent Secured in Countries Across Europe- -Bavituximab Phase III Clinical Trial Underway at Over 150 Worldwide Clinical Sites Including Over 75 Sites in Eight European Countries- ...

TUSTIN, Calif., June 5, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment...

- New Data Show that Bavituximab Alone and in Combination with Docetaxel Elicits a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients - - PS-Targeting Antibodies...

- Phase II Trial to Evaluate Combination of Bavituximab and Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer - - Phase II/III Combination Trial to Advance Bavituximab with Chemotherapy...

TUSTIN, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology...

TUSTIN, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology (I-O)...

TUSTIN, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology...

- Combination Treatment Reduces Tumor Immune System Blockade and Enhances Tumor Specific Immune Responses - - Studies Reveal Significant Increases in Tumor-Infiltrating CD8+ T Cells and...